Jyoti Yellol

Novel C,N-Cyclometalated Benzimidazole Ruthenium(II) and Iridium(III) Complexes as Antitumor and Antiangiogenic Agents: A Structure–Activity Relationship Study

Jyoti Yellol, Sergio A. Pérez, Alicia Buceta et al. · Journal of Medicinal Chemistry · 2015 · 153 citations

Natural Sciences, Chemistry, Medicinal Chemistry +16

On the antitumor properties of novel cyclometalated benzimidazole Ru(ii), Ir(iii) and Rh(iii) complexes

Gorakh S. Yellol, Antonio Donaire, Jyoti Yellol et al. · Chemical Communications · 2013 · 121 citations

Pharmacy, Pharmacology, Drug Discovery +1

Synthesis of 2-Pyridyl-benzimidazole Iridium(III), Ruthenium(II), and Platinum(II) Complexes. Study of the Activity as Inhibitors of Amyloid-β Aggregation and Neurotoxicity Evaluation

Gorakh S. Yellol, Jyoti Yellol, Vijaya B. Kenche et al. · Inorganic Chemistry · 2014 · 72 citations

Pharmacy, Medicinal Chemistry, Pharmacology +16

Highly potent extranuclear-targeted luminescent iridium(<scp>iii</scp>) antitumor agents containing benzimidazole-based ligands with a handle for functionalization

Jyoti Yellol, Sergio A. Pérez, Gorakh S. Yellol et al. · Chemical Communications · 2016 · 66 citations

Medicine, Medicinal Chemistry, Oncology +14

Organoruthenium Complexes with C^N Ligands are Highly Potent Cytotoxic Agents that Act by a New Mechanism of Action

Vojtěch Novohradský, Jyoti Yellol, Olga Stuchlíková et al. · Chemistry - A European Journal · 2017 · 35 citations

Medicine, Medicinal Chemistry, Pharmacology +11